PLX's future strategic direction should be focused on maximizing use of their technology
Announcing a new strategic direction for the company in which they offer the technology for modest upfront fee for a NON-exclusive license plus 5% future royalty on future sales will have all the generic manufacturers knocking on their door. Signing their first deal with South Korea's Hanwha Chemical will cause their stock price to explode. Hanwha is the South Korean biosimilars manufacture that Merck teamed up with to bring its biosimilar version of Amgen's Enbre to market, until the USPTO extended Amgen's patent for another 16 years. Partner with Hanwha and they will get Merck's attention. Merck is ready to stab all these big pharma's in the back and steal their highly profitable drugs sales.
Sign Teva, Hospira and Celltrion right after Hanwha and Protalix's market cap will instantly grow beyond the takeover aspirations of Pfizer.
Protalix management should've spoken to Merck not Pfizer about a takeover. $2 billion is nothing if it gives Merck a way around their competitions method based (Chinese Hamster Ovary cells) manufacturing patents.
i'm losing lot of money in this stock. ZACKS gives plx strong buy.
but i think that only within 10 years something good will happen, not sure.
i feel very stupid to hold plx, and listen to analysts.
still i hold it with hopes.